Bupropion - Articles | CARLAT PUBLISHING

Research Update

How Do We Help Depressed Smokers Quit?

October 1, 2024

Justin Morales, MD and Deepti Anbarasan, MD

Justin Morales, MD, and Deepti Anbarasan, MD. Drs. Morales and Anbarasan have no financial relationships with companies related to this material.

Tobacco smoking and major depression are highly comorbid, and depressed patients usually have a tougher time quitting than their non-depressed counterparts. In this research study, investigators compared the efficacy of anti-smoking medications in those with depression. The results may surprise you.

Research Update

Efficacy of Auvelity for Major Depression

April 1, 2024

Nina Chandler, DNP, APRN, PMHNP-BC

Nina Chandler, DNP, APRN, PMHNP-BC. Dr. Chandler has no financial relationships with companies related to this material.

A dextromethorphan-bupropion combo tablet shows promise in treating major depression. The FDA recognized its potential in 2019, so stay tuned for more updates on this novel treatment.

Uncontrolled Misuse

October 23, 2023

Chris Aiken, MD and Kellie Newsome, PMHNP

There are many reasons why patients misuse medications. Today, Joseph Pierre shakes us out of our 1990s understanding of addiction and explains a new trend, misuse of uncontrolled medications like Bupropion, Quetiapine and the Gabapentinoids.

Clinical Update

Are Two Antidepressants Better Than One?

July 3, 2023

Michael Posternak, MD.

Michael Posternak, MD. Psychiatrist in private practice, Boston, MA.

Dr. Posternak has no financial relationships with companies related to this material.

New research calls to question the common practice of antidepressant combinations. Dr. Posternak makes sense of it.

Clinical Update

Treatment of Antipsychotic-Induced Weight Gain

September 1, 2022

Brian Miller, MD, PhD, MPH

Brian Miller, MD, PhD, MPH. Professor of Psychiatry at the Medical College of Georgia, Augusta, and President of the Georgia Psychiatric Physicians Association.

Dr. Miller, author of this educational activity, receives research support from Augusta University; the National Institute of Mental Health; the Brain and Behavior Research Foundation; and the Stanley Medical Research Institute. Relevant financial relationships listed for the author have been mitigated.

From lifestyle changes to liraglutide, Brian Miller details best practices for managing this insidious side effect.

CLINICAL UPDATE

Six Tips From Prescribing Psychotropics

August 1, 2022

Chris Aiken, MD

Chris Aiken, MD.

Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC.

Dr. Aiken, author for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

New answers to age-old questions, such as adjusting the dose to account for drug interactions, reducing side effects, maintaining weight, and protecting that finicky organ—the kidneys.

Battle of the Bulge: Obesity and Antipsychotic-Induced Weight Gain

July 14, 2021

Farah Khorassani, PharmD. Clinical Assistant

Farah Khorassani, PharmD. Clinical Assistant Professor of Pharmacy Practice, St. John’s University, Queens, NY. Dr. Khorassani has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

With so many weight loss medications on the market, it’s hard to know which to choose. Dr. Khorassani tells us everything we need to know to about selecting and prescribing these agents. Also, she gives us additional tips for managing antipsychotic-induced weight gain.

The Psychopharmacology Algorithm Project

March 30, 2020

David Osser, MD

David Osser, MD

General Editor of the Psychopharmacology Algorithm Project at the Harvard South Shore Psychiatry Residency Training Program and Associate Professor of Psychiatry at Harvard University. Dr. Osser has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dr. Osser set out to develop a psychopharmacology algorithm that actually changes practice. He speaks to us on antidepressants in bipolar, psychoses that don’t need antipsychotics, and his top picks for bipolar mania, bipolar depression, and unipolar depression.

Optimal Antidepressant Doses in Major Depression

March 9, 2020

Kristen Gardner, PharmD.

Kristen Gardner, PharmD. Dr. Gardner has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

More is not necessarily better in psychopharmacology. Some medications have plateau effect, while others follow a “U-shaped curve,” causing more problems as the dose goes too high. This metaanalysis looked at 77 dose-response trials with antidepressants to quantify their optimal therapeutic window.

EXPERT Q&A

Inflammatory Biomarkers in Depression

February 10, 2020

Andrew H. Miller, MD

Andrew H. Miller, MD

William P. Timmie Professor of Psychiatry and Behavioral Sciences, Emory University, GA Dr. Miller has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Andrew Miller, Vice Chair of Psychiatry Research at Emory University, translates two decades research on inflammation and depression into practical terms, including a low-cost biomarker that may guide antidepressant selection.